Navigation Links
Wistar researchers: Direct proof of how T cells stay in 'standby' mode

For much of the time our T cellsthe white blood cells that act as the police of the immune systemare in what immunologists call a "quiescent state," a sort of standby mode. For years, scientists have wondered if quiescence occurred by default or whether T cells need to work at remaining silent. Now, researchers at The Wistar Institute provide the first direct proof that a protein, called Foxp1, actively maintains this state of quiescence in T cells until the cells are called upon by other parts of the immune system.

Their findings, which appear online through Nature Immunology ahead of print publication, could one day enable researchers to activate T cells to fight diseases such as cancer, which can go undetected or unrecognized by the immune system. In fact, the researchers report that knocking out the Foxp1 protein in mice activates T cells, allowing the cells to work in their policing function.

"T cell quiescence has been a big mystery in immunology with some obvious and profound implications for treating illness by manipulating the immune system," said Hui Hu, Ph.D., senior author of the study and assistant professor in the Immunology Program at The Wistar Institute. "We believe we have provided evidence that quiescence is not just a passive, default state, and we are now beginning to understand the molecular mechanisms by which it happens."

Mature T cells are generated in the thymus, an organ located in front of heart, and then exit into the periphery. There, these T cells are in a "nave," quiescent state, awaiting orders to act. Activation primarily requires antigen-presenting cell, which offers up an antigen (a particle that the immune system recognizes as "foreign") to the T cell Receptor (TCR). This activated TCR, then, gives the T cell specificity.

Foxp1 is a transcription factor, a protein that binds to DNA and causes the cell to reador transcribespecific genes. The Hu laboratory had previously shown that the Foxp1 protein is important for T cell development in the thymus. In order to understand how Foxp1 operates in mature T cells, the researchers used an inducible deletion model system where they could choose to delete the gene's activity after the cells have already matured.

In studying these Foxp1-less T cells, Hu and his colleagues discovered that naive T cells without Foxp1 become activated and proliferate in response to the protein IL-7, without antigen triggers. Hu and his colleagues discovered that Foxp1 represses the expression of the receptor for IL-7, and some other key signaling, in regulating T cell quiescence.

Foxp1, the researchers found, is similar to a related transcription factor, called Foxo1, a well-studied protein with numerous roles in both cancer and aging. In T cells, Foxo1 helps induce the creation of IL-7 receptors, which allows the T cell to receive the IL-7 signal. Foxp1, they found, directly competed with Foxo1's DNA binding spot, thereby limiting the number of IL-7 receptors each T cell has. Such inter-protein competition helps maintain a balanced state within the cell, Hu says.

Among their key findings, Hu believes, is that removing Foxp1 can cause T cells to proliferate without triggering the TCR. "Antigenic specificity is the key characteristic of T cells and our adaptive immunity," Hu. Said. "We never thought a naive T cell could be activated without stimulation through the T cell receptor."

"It came as such a surprise that the deletion of Foxp1, basically the removal of an essential negative regulation, could lead naive T cells to bypass overt antigen recognition and become activated with effector functions," Hu.

According to Hu, his laboratory, in collaboration with fellow laboratories at Wistar, are now investigating the possibility of knocking out Foxp1 to stimulate T cells in the tumor microenvironment.

"Many cancers cause local T cells to become effectively unresponsive or 'quiescent,' thereby allowing tumors to grow unimpeded by the immune system," Hu said. "We suspect that the tumor cells may 'hijack' the cell-intrinsic quiescence mechanism. In addition, many tumor antigens are poorly immunogenic. By manipulating Foxp1 expression, we may bypass the poor tumor antigen stimulation and restore T cell activation within tumors in the hopes that the immune system will clear away cancerous cells."


Contact: Greg Lester
The Wistar Institute

Related medicine news :

1. Wistar researchers follow a path to a potential therapy for NF2, a rare tumor disorder
2. Wistar researchers discover new class of objects encoded within the genome
3. Wistar scientists explain the persistence of melanoma through dynamic stemness
4. Researchers: Sexually active teens need confidential health care
5. Researchers: Elderly patients 4 times more likely to die from treatment complications
6. Researchers: Pay more attention to epilepsy
7. Ben-Gurion U. researchers: High resistance rates among acute otitis media pathogens in children
8. IU researchers: Chemotherapy alters brain tissue in breast cancer patients
9. New direction for epilepsy treatment
10. Center director says FDA hitting milestones in tobacco law
11. How we manage water resources has a direct impact on our health, says Canada Research Chair
Post Your Comments:
(Date:11/28/2015)... ... ... Trying to relax on a couch can actually be uncomfortable, so an inventor ... to personal experience with a bad back," he said. , This easy-to-use, versatile invention ... increases support. It also makes it easier to eat, do other activities and charge ...
(Date:11/27/2015)... ... 2015 , ... According to an article published November 13th on ... Washington D.C. revolved around the fact that proper dental care, both at-home and in ... link between periodontal disease (more commonly referred to as gum disease) and diabetes. According ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors ... treat it. Surviving Mesothelioma has just posted the findings on the website. Click ... analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed by ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions ... SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of ... SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
(Date:11/25/2015)...  The total global healthcare industry is expected to grow ... Latin America has the highest projected growth at ... Japan ), is second with growth projected at 11.5%. ... healthcare expenditure. In 2013-2014, total government funded healthcare was nearly ... to 41.2% in 2013-2014. In real terms, out of pocket ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
Breaking Medicine Technology: